ForumIAS LATEST
- SFG FRC 2027 | Program starts from 19th Dec. 2026 | Admissions open for Entrance Test Click Here to know more →
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →
News: Biocon drug Itolizumab has been approved by the Drugs Controller General of India(DCGI) for treating moderate to severe Covid-19 patients.
Facts:
- Itolizumab: It is a monoclonal antibody drug manufactured by Biocon for the treatment of severe chronic plaque psoriasis.
- Monoclonal antibodies are lab-made proteins that act like human antibodies in the immune system and fight against foreign molecules.
- How will it work? Itolizumab will be used for the treatment of cytokine release syndrome(CRS) in moderate to severe COVID-19 patients.
Additional Facts:
- Cytokine release syndrome(CRS): It is a systemic inflammatory response that can be triggered by a variety of factors such as infections and other diseases.
- DCGI: It is a department of the Central Drugs Standard Control Organization(CDSCO) responsible for approval of licences of specified categories of drugs such as blood and blood products, IV fluids and vaccines in India.It comes under the Ministry of Health & Family Welfare.
